Literature DB >> 27535566

MassARRAY, pyrosequencing, and PNA clamping for EGFR mutation detection in lung cancer tissue and cytological samples: a multicenter study.

Kyueng-Whan Min1, Wan-Seop Kim2, Se Jin Jang3, Yoo Duk Choi4, Sunhee Chang5, Soon Hee Jung6, Lucia Kim7, Mee-Sook Roh8, Choong Sik Lee9, Jung Weon Shim10, Mi Jin Kim11, Geon Kook Lee12.   

Abstract

BACKGROUND: Testing for epidermal growth factor receptor (EGFR) mutation is an important process in the therapeutic plan of patients with lung cancer. Recently, MassARRAY, based on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, has been shown to be a useful method for somatic mutation analysis with pyrosequencing and peptide nucleic acid clamping (PNAc).
METHODS: A total of 107 tissues and 67 cytological samples, which were confirmed to have lung adenocarcinoma at nine hospitals in Korea, were collected. Among the MassARRAY, pyrosequencing, and PNAc, the concordance rates and sensitivity of EGFR mutation detection were analyzed and validated in comparative tissue and cytological specimens.
RESULTS: The concordance rate between pyrosequencing and PNAc was higher than that between MassARRAY and either of the pyrosequencing and PNAc in both tissue and cytological samples. In a comparison of diagnostic performance, MassARRAY (sensitivity: 85.7 %) was higher than pyrosequencing (74.3 %) and PNAc (70 %) in tissue, although pyrosequencing (80.5 %) was more highly sensitive, compared to MassARRAY (70.7 %) and PNAc (70.7 %) in terms of cytology. Unexpectedly, use of MassARRAY resulted in a significantly different EGFR mutation detection rate between tissue and cytological samples.
CONCLUSIONS: When used for the detection of EGFR mutations, MassARRAY was more sensitive than pyrosequencing or PNA clamping in tissue, but not in cytological samples. In EGFR mutation detection between tissues and cytology, PNAc showed relatively higher concordance than MassARRAY or pyrosequencing.

Entities:  

Keywords:  EGFR mutation; Lung adenocarcinoma; Mass spectrometry, pyrosequencing; Peptide nucleic acid

Mesh:

Substances:

Year:  2016        PMID: 27535566     DOI: 10.1007/s00432-016-2211-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  29 in total

1.  MassARRAY spectrometry is more sensitive than PreTect HPV-Proofer and consensus PCR for type-specific detection of high-risk oncogenic human papillomavirus genotypes in cervical cancer.

Authors:  Partha Basu; Puneet Chandna; R N K Bamezai; Maqsood Siddiqi; Dhananjaya Saranath; Adrian Lear; Sam Ratnam
Journal:  J Clin Microbiol       Date:  2011-08-03       Impact factor: 5.948

2.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

3.  Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.

Authors:  Takahiro Nakajima; Kazuhiro Yasufuku; Akira Nakagawara; Hideki Kimura; Ichiro Yoshino
Journal:  Chest       Date:  2011-04-28       Impact factor: 9.410

4.  Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing.

Authors:  Fiamma Buttitta; Lara Felicioni; Maela Del Grammastro; Giampaolo Filice; Alessia Di Lorito; Sara Malatesta; Patrizia Viola; Irene Centi; Tommaso D'Antuono; Roberta Zappacosta; Sandra Rosini; Franco Cuccurullo; Antonio Marchetti
Journal:  Clin Cancer Res       Date:  2012-12-14       Impact factor: 12.531

5.  A tissue fixative that protects macromolecules (DNA, RNA, and protein) and histomorphology in clinical samples.

Authors:  Vladimir Vincek; Mehdi Nassiri; Mehrdad Nadji; Azorides R Morales
Journal:  Lab Invest       Date:  2003-10       Impact factor: 5.662

6.  Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas.

Authors:  Renu Khode; Douglas A Larsen; Brianne C Culbreath; Shane Parrish; Kimberly L Walker; Lubna Sayage-Rabie; Robert S Beissner; Arundhati Rao
Journal:  Cancer Cytopathol       Date:  2013-01-30       Impact factor: 5.284

7.  Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues.

Authors:  Sandrine Dufort; Marie-Jeanne Richard; Florence de Fraipont
Journal:  Anal Biochem       Date:  2009-05-21       Impact factor: 3.365

8.  Sensitive and rapid detection of viruses associated with hand foot and mouth disease using multiplexed MALDI-TOF analysis.

Authors:  Junping Peng; Fan Yang; Zhaohui Xiong; Junhua Guo; Jiang Du; Yongfeng Hu; Qi Jin
Journal:  J Clin Virol       Date:  2012-11-26       Impact factor: 3.168

9.  Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.

Authors:  Ronald van Eijk; Jappe Licht; Melanie Schrumpf; Mehrdad Talebian Yazdi; Dina Ruano; Giusi I Forte; Petra M Nederlof; Maud Veselic; Klaus F Rabe; Jouke T Annema; Vincent Smit; Hans Morreau; Tom van Wezel
Journal:  PLoS One       Date:  2011-03-08       Impact factor: 3.240

10.  Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey.

Authors:  Sang Hwa Lee; Wan Seop Kim; Yoo Duk Choi; Jeong Wook Seo; Joung Ho Han; Mi Jin Kim; Lucia Kim; Geon Kook Lee; Chang Hun Lee; Mee Hye Oh; Gou Young Kim; Sun Hee Sung; Kyo Young Lee; Sun Hee Chang; Mee Sook Rho; Han Kyeom Kim; Soon Hee Jung; Se Jin Jang
Journal:  J Pathol Transl Med       Date:  2015-10-13
View more
  4 in total

1.  MassARRAY multigene screening combined with LDL-C and sdLDL-C detection for more favorable outcomes in type 2 diabetes mellitus therapy.

Authors:  Yong Tian; Junhong Wang; Yanxiao Liu; Xiangguang Luo; Ziying Yao; Xinjun Wang; Yuanyuan Zhang; Cheng Xu; Xiaoyu Zhao
Journal:  BMC Med Genomics       Date:  2021-03-17       Impact factor: 3.063

2.  Lung cancer mutation testing: a clinical retesting study of agreement between a real-time PCR and a mass spectrometry test.

Authors:  Phillip Shepherd; Karen L Sheath; Sandar Tin Tin; Prashannata Khwaounjoo; Phyu S Aye; Angie Li; George R Laking; Nicola J Kingston; Christopher A Lewis; J Mark Elwood; Donald R Love; Mark J McKeage
Journal:  Oncotarget       Date:  2017-09-16

Review 3.  Non-small cell lung cancer in China.

Authors:  Peixin Chen; Yunhuan Liu; Yaokai Wen; Caicun Zhou
Journal:  Cancer Commun (Lond)       Date:  2022-09-08

4.  Noninvasive circulating tumor cell and urine cellular XPC (rs2228001, A2815C) and XRCC1 (rs25487, G1196A) polymorphism detection as an effective screening panel for genitourinary system cancers.

Authors:  Cen Wu; Cheng Xu; Guaxiu Wang; Dahu Zhang; Xiaoyu Zhao
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.